News details

 
Information title

Novel Agent Produces Sustained Benefit in Mild to Moderate AD

Published on Thursday 07 August 2008 - 17:58

Summary :
New data from an open-label 6-month extension trial of Dimebon, an agent with a novel neuroprotective effect, indicates the drug may have sustained clinical benefit in mild-to-moderate Alzheimer's...
Read more

Information source

Medscape Medical News Headlines

http://www.medscape.com/welcome/news?src=rss

Website description
Latest medical news from Medscape

Articles published on this website : 0 / 7 days - 0 / 30 days

Low Early Cognitive Ability a Risk Factor for Long-Term Combination Alzheimer's Therapy Slows Decline Transcranial Stimulation Improves Memory in Alzheimer's Disease PET Scans May Detect Beta-Amyloid Deposition Linked to Low-Flow CSF Draining of No Benefit in Alzheimer

Other articles published on other websites on the same day

Rethinking Alzheimer's http://www.businessweek.com/ Satoris Eyeing Launch of Alzheimer’s Test While Awaiting Validation Results http://www.proteomonitor.com/ KU professor awarded $2.1 million NIH grant http://www2.ljworld.com/ KU professor awared $2.5 million NIH grant http://www2.ljworld.com/ From Allergy to Alzheimer's Treatment http://www.tfot.info/ Conference points out wins, misses in Alzheimer's research http://www.yourwestvalley.com/ Woman raises $16,000 for Alzheimer's research http://hoinews.com/ Gene mutation not a risk factor for concussion http://www.healthcentral.com/ Alzheimer's Association to hold support group http://www.montereyherald.com/ Chemist who unlocked mystery to create diamonds http://www.theage.com.au/